Axxam validates cardiac organoid platform developed by Molecular Devices and HeartBeat.bio for drug discovery and early derisking

Axxam S.p.A., a premier provider of integrated early drug discovery services, today announced the successful validation of a scalable 3D human cardiac organoid platform developed by Molecular Devices, LLC. in collaboration with HeartBeat.bio. Built on HeartBeat.bio's proprietary Cardioid technology, the platform enables researchers to generate reproducible, physiologically relevant cardiac organoids (Cardioids) at scale for drug toxicity and safety assessment.